Neuronetics Inc. (STIM)
NASDAQ: STIMHealth CareMedical/Dental InstrumentsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
STIM stock chart
Technical analysisKey statistics
All statistics- Market cap
- $120.60M
- EPS (TTM)
- -$0.32
- Dividend yield
- None
- 52-week range
- 0.80 – 3.44
- Day range
- 1.12 – 1.26
- Volume / Avg
- 2.99M / 1.76M
- Beta
- —
- Shares outstanding
- 96.48M
52-week range
STIM stock today
Neuronetics (STIM) closed at $1.25 on Nov 20, up 0.81% (+$0.01), versus the S&P 500's 3.70% decline. Shares are 63.7% below their 52-week high of $3.44, set on Aug 11, 2026 and 56.2% above the 52-week low of $0.80, near the bottom of the past year's range. STIM is down 9.4% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 4.6%.
Neuronetics has posted a net loss over the last twelve months (EPS of -$0.32), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Neuronetics
Company profileNeuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally. The company provides NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- CEO
- Mr. Daniel L. Reuvers
- Headquarters
- Malvern, PA
- Employees
- 658
- IPO year
- 2018
- Website
- neurostar.com/neuronetics
Financial highlights
Full financialsIn fiscal 2025, Neuronetics generated $149.2 million in revenue, up 99.2% from fiscal 2024, its 5th consecutive year of revenue growth. Neuronetics reported a net loss of $39.0 million, compared with a loss of $43.7 million a year earlier. Gross margin was 48.5% (down from 72.3%) and operating margin -21.1%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $149.16M | $74.89M | $71.35M | $65.21M | $55.31M |
| Growth | +99.17% | +4.96% | +9.42% | +17.89% | +12.32% |
| Net income | $-39.00M | $-43.71M | $-30.19M | $-37.16M | $-31.19M |
| EPS (diluted) | $-0.59 | $-1.38 | $-1.05 | $-1.38 | $-1.22 |
Analyst forecast
ForecastConsensus (4 analysts)
strong_buy
Avg. price target
$6.00+380.00%
- Strong buy 1
- Buy 3
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 4, 2026
- EPS actual vs est.
- $-0.13 vs $-0.08
- Surprise
- -62.50%
STIM news
All STIM news- Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Business Insider
- Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Neuronetics, Inc. Announces Pricing of $30 Million Underwritten Public Offering of Common StockNasdaq
- Neuronetics Prices $30 Mln Offering Of Shares At $1.60/Shr; Plans Debt Repayment; Stock DownNasdaqSTIM, LEN.B
- Neuronetics Announces Pricing of $30 Million Underwritten Public Offering of Common StockGlobeNewswire
- Neuronetics Announces Proposed Public Offering of Common StockGlobeNewswire
- Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Neuronetics, Inc. Reports Third Quarter 2026 Financial and Operating ResultsNasdaq
Neuronetics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| LUNGPulmonx Corporation | 2.57 | -6.20% | $111.93M | vs STIM |
| PYPDPolyPid Ltd. | 6.12 | -6.56% | $129.29M | vs STIM |
| APYXApyx Medical Corporation | 2.40 | +0.42% | $101.10M | vs STIM |
| KRMDKORU Medical Systems Inc. | 3.19 | -7.27% | $138.37M | vs STIM |
| NYXHNyxoah SA | 0.805 | -7.01% | $81.98M | vs STIM |
| SKINSkinHealth Systems Inc. Class A | 11.77 | -3.13% | $76.68M | vs STIM |
| LUCDLucid Diagnostics Inc. | 0.3727 | -3.52% | $72.57M | vs STIM |
| QTEXQTREX Quantum Ltd. | 1.00 | -10.71% | $70.63M | vs STIM |
Indexes, lists and sector
Neuronetics stock FAQ
What is Neuronetics's stock price today?
STIM last traded at $1.25 as of Nov 20, 4:00 PM EST, up 0.81% on the day. Prices are delayed at least 15 minutes.
Who is Neuronetics's CEO?
Mr. Daniel L. Reuvers is the chief executive officer of Neuronetics Inc., which has about 658 employees.
What is the STIM 52-week high?
The 52-week high for STIM is $3.44 and the 52-week low is $0.80. The stock is currently 63.7% below its high.